Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions

Colistin as a first choice antibiotic for the initial empiric antimicrobial therapy of ventilator-associated pneumonia

K. Ioannides, P. Myrianthefs, G. Baltopoulos
European Respiratory Journal 2007 30: 1234-1235; DOI: 10.1183/09031936.00102207
K. Ioannides
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
P. Myrianthefs
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
G. Baltopoulos
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

To the Editors:

We read with great interest the article recently published in the European Respiratory Journal (ERJ) by Rios et al. 1 regarding ventilator-associated pneumonia (VAP) due to colistin susceptible-only microorganisms. The authors concluded that colistin could be a suitable antibiotic for the initial empiric antimicrobial therapy in their intensive care unit (ICU) since they identified 30 carbapenem-sensitive (Carb-S) and 31 colistin-sensitive (Col-S) isolates.

In our seven-bed general ICU 184 patients were admitted during a period of 18 months with the following characteristics: 125 (67.9%) males; age (mean±sd) 57.8±22.7 yrs; Simplified Acute Physiology Score II 48.2±11.8; Acute Physiology and Chronic Health Evaluation II 19.1±5.7; mean ICU stay 36.7±36.9 days; mean mechanical ventilation duration 29.2±15.9 days; and a total of 3,262 ventilator days.

A total of 52 (28.3%) VAP episodes (15.9 episodes per 1,000 ventilator days, with a mean clinical pulmonary infection score at VAP onset of 7.4±1.6) were identified, of which 13 (25%) were early- and 39 (75%) late-onset VAP. The mortality rate was 19%, i.e. 10 out of 52 patients, of which: four were attributed to inappropriate treatment; five to delayed antibiotic treatment; and one to inappropriate and delayed treatment.

We had 56 (four patients with two pathogens) isolates from respiratory specimen cultures, all of them Gram-negative microorganisms: 45 Acinetobacter baumannii, nine Pseudomonas aeruginosa and two Klebsiella pneumoniae. Susceptibility results are shown in table 1⇓.

View this table:
  • View inline
  • View popup
Table 1—

Susceptibility results for microorganisms in early and late ventilator-associated pneumonia

According to our results, we had 50 Carb-S and only six Col-S isolates, which is a significant difference compared with the study by Rios et al. 1. Also, only eight of the 50 Carb-S isolates were sensitive to imipenem but all 50 were meropenem sensitive (Mer-S). Another difference with that study 1 is that 41 gentamicin-sensitive (Gent-S) isolates were identified.

We also found that late-onset VAP due to P. aeruginosa may be Col-S and, in part, sensitive to piperacilline-tazobactam, while early-onset VAP due to P. aeruginosa is multisensitive. Conversely, pneumonia due to A. baumannii, even in early VAP, may be mainly due to multidrug-resistant species (41 out of 45) and specifically Gent-S, Mer-S and Col-S (35, 43 and 45 out of 45 patients, respectively).

Summarising our results, out of 56 isolates, 10 were multi-sensitive isolates, 41 were Gent-S, 50 Mer-S and 56 Col-S, with only six of the 56 isolates identified as colistin-susceptible only.

According to our ecology and sensitivities and despite several differences regarding isolated pathogens and sensitivities compared with that study 1, colistin should be considered as an antibiotic for the initial empiric management of VAP. Gentamicin could not be used as an alternative choice in empiric treatment as it covers only 73.2% of the isolates. Using colistin with or without meropenem, all possible pathogens can be covered and then treatment de-escalated according to susceptibility results.

This practice is in accordance with the American Thoracic Society (ATS)/Infectious Diseases Society and America (IDSA) guidelines 2, which recommend consideration of local microbiological data when selecting empiric treatment for VAP and that each hospital and ICU should ideally have their own antibiograms, which should be updated as often as possible. The ATS/IDSA guidelines 2 suggest also considering colistin for the management of VAP attributed to carbapenem-resistant Acinetobacter spp. Also, it has been suggested that each ICU should design specific empiric treatment protocols that are likely to be effective according to local microbiology and resistance patterns 3. Finally, and according to this concept, Beardsley et al. 4 recently published a significant article introducing the first institution-specific developed guidelines for the management of hospital-acquired pneumonia.

It is important to note the daily costs of meropenem (2 gr×3 = 6 gr i.v. daily; AstraZeneca, Macclesfield, UK) and colistin therapy (3 million IU×3 = 9 million i.v. daily; Norma, Athens, Greece), which are \#8364;241,032 and \#8364;13,68, respectively! Also we would like to inform the readers of the ERJ that we did not experience significant adverse effects with colistin use, i.e. nephrotoxicity requiring discontinuation of the drug or dialysis, except a transient elevation of creatinine ≤1.6 mg·dL−1 in three patients, which was normalised after adjustment of colistin dosing to creatinine clearance.

In conclusion, we totally agree with Rios et al. 1 suggesting colistin as a suitable antibiotic for the initial empiric antimicrobial therapy in intensive care units with carbapenem resistant pathogens.

    • © ERS Journals Ltd

    References

    1. ↵
      Rios FG, Luna CM, Maskin B, et al. Ventilator-associated pneumonia due to colistin susceptible-only microorganisms. Eur Respir J 2007;30:307–313.
      OpenUrlAbstract/FREE Full Text
    2. ↵
      American Thoracic Society, Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005;171:388–416.
      OpenUrlCrossRefPubMedWeb of Science
    3. ↵
      Torres A, Ewig S. Diagnosing ventilator-associated pneumonia. N Engl J Med 2004;350:433–435.
      OpenUrlCrossRefPubMedWeb of Science
    4. ↵
      Beardsley JR, Williamson JC, Johnson JW, Ohl CA, Karchmer TB, Bowton DL. Using local microbiologic data to develop institution-specific guidelines for the treatment of hospital-acquired pneumonia. Chest 2006;130:787–793.
      OpenUrlCrossRefPubMedWeb of Science
    PreviousNext
    Back to top
    View this article with LENS
    Vol 30 Issue 6 Table of Contents
    European Respiratory Journal: 30 (6)
    • Table of Contents
    • Index by author
    Email

    Thank you for your interest in spreading the word on European Respiratory Society .

    NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

    Enter multiple addresses on separate lines or separate them with commas.
    Colistin as a first choice antibiotic for the initial empiric antimicrobial therapy of ventilator-associated pneumonia
    (Your Name) has sent you a message from European Respiratory Society
    (Your Name) thought you would like to see the European Respiratory Society web site.
    CAPTCHA
    This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
    Print
    Citation Tools
    Colistin as a first choice antibiotic for the initial empiric antimicrobial therapy of ventilator-associated pneumonia
    K. Ioannides, P. Myrianthefs, G. Baltopoulos
    European Respiratory Journal Dec 2007, 30 (6) 1234-1235; DOI: 10.1183/09031936.00102207

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero

    Share
    Colistin as a first choice antibiotic for the initial empiric antimicrobial therapy of ventilator-associated pneumonia
    K. Ioannides, P. Myrianthefs, G. Baltopoulos
    European Respiratory Journal Dec 2007, 30 (6) 1234-1235; DOI: 10.1183/09031936.00102207
    del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
    Full Text (PDF)

    Jump To

    • Article
      • References
    • Figures & Data
    • Info & Metrics
    • PDF
    • Tweet Widget
    • Facebook Like
    • Google Plus One

    More in this TOC Section

    • Wider access to quality-assured rifapentine-based regimens is needed to accelerate tuberculosis prevention and care globally
    • The alarmin(g) effect of interleukin-5 blockade on residual eosinophil function is of clinical consequence
    • The association between immunosuppressant and the outcome of COVID-19
    Show more Correspondence

    Related Articles

    Navigate

    • Home
    • Current issue
    • Archive

    About the ERJ

    • Journal information
    • Editorial board
    • Reviewers
    • Press
    • Permissions and reprints
    • Advertising

    The European Respiratory Society

    • Society home
    • myERS
    • Privacy policy
    • Accessibility

    ERS publications

    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS books online
    • ERS Bookshop

    Help

    • Feedback

    For authors

    • Instructions for authors
    • Publication ethics and malpractice
    • Submit a manuscript

    For readers

    • Alerts
    • Subjects
    • Podcasts
    • RSS

    Subscriptions

    • Accessing the ERS publications

    Contact us

    European Respiratory Society
    442 Glossop Road
    Sheffield S10 2PX
    United Kingdom
    Tel: +44 114 2672860
    Email: journals@ersnet.org

    ISSN

    Print ISSN:  0903-1936
    Online ISSN: 1399-3003

    Copyright © 2022 by the European Respiratory Society